No, melanoma does not itch constantly in most cases, and itch is neither a reliable nor a required feature of the disease. When melanoma itch does occur, it is usually intermittent rather than constant, and it can reflect tumor-nerve interactions, local inflammation, or barrier disruption in the skin. Roughly a quarter of melanoma patients report itching at some point, which means the symptom is common enough to matter but far too inconsistent to serve as a screening test on its own.

The Mechanism Behind Melanoma Itch

Itch in melanoma arises from a conversation between tumor cells and the cutaneous sensory nervous system. The skin is densely innervated by unmyelinated C-fibers that carry itch signals, and these fibers express receptors such as TRPV1 and PAR2. When melanoma cells release inflammatory mediators, including histamine, proteases, and cytokines like interleukin-6, those receptors fire and the brain registers itch.

Melanoma also grows along and into nerve bundles, a process called perineural invasion. This mechanical and chemical disturbance can sensitize local nerve endings, lowering their firing threshold so that ordinary stimuli provoke itch. The same sensitization explains why melanoma itch is often focal, confined to or near the lesion, rather than diffuse.

A second pathway matters: keratinocyte-derived itch mediators. As melanoma disrupts the epidermis and its barrier, keratinocytes release thymic stromal lymphopoietin and other alarmins that directly activate sensory neurons. This is why superficial spreading melanoma, which stays closer to the surface longer, may itch more than a deep nodular lesion that has already breached the dermis.

One counterintuitive detail: itch in melanoma is not primarily histaminergic. Antihistamines often fail because the dominant drivers are proteases and cytokines acting on non-histamine receptors. A patient whose lesion itch does not respond to over-the-counter antihistamines has not ruled melanoma out; the drug simply targets the wrong pathway.

How Common Is Melanoma Itch, Really?

Quantified estimates vary by study design, which is itself instructive. Surveys of melanoma patients put the prevalence of itch somewhere between 20 and 30 percent, with higher figures in studies that ask specifically about the lesion rather than the whole body. Nodular and acral lentiginous subtypes tend to report itch less often than superficial spreading lesions.

Compare this with basal cell carcinoma, where itching is reported in roughly 30 to 40 percent of cases in dermatology series, and squamous cell carcinoma, which frequently itches because of marked inflammation and keratinization. In other words, itch is a shared feature of several skin cancers and does not discriminate between them. Its presence raises suspicion; its absence says nothing.

The numbers also shift with lesion size and duration. Larger lesions and those present for longer periods more often produce symptoms, consistent with progressive nerve involvement. A new, small, symmetric nevus that itches occasionally is statistically unlikely to be melanoma, while a changing, asymmetric lesion that has begun to itch deserves prompt evaluation regardless of size.

Edge Cases That Complicate the Picture

Amelanotic melanoma, which lacks visible pigment, is a notorious edge case. Because it presents as a pink or flesh-colored nodule or macule, it mimics eczema, psoriasis, or a bug bite, and itch becomes one of the few symptoms that prompts a patient to seek care. Here itch is less a distraction and more a red-flag generator.

Acral melanoma on palms, soles, and nail beds behaves differently. The thick stratum corneum and dense nerve supply of acral skin mean itch, when present, can be intense and is easily attributed to calluses or fungal infection. Subungual melanoma may present with itching of the nail bed alongside pigmented streaks.

Mucosal and ocular melanomas rarely itch in the conventional sense because they lack the same cutaneous innervation, though ocular melanoma can cause irritation or a foreign-body sensation. And in older adults, chronic pruritus from xerosis, renal disease, or cholestasis can coexist with a melanoma and confound attribution, making the lesion itself the anchor for evaluation rather than the symptom alone.

Misconceptions Worth Retiring

The most persistent misconception is that a lesion that does not itch is safe. Most melanomas are asymptomatic at diagnosis, and the ABCDE criteria do not include itch for exactly this reason. Itch is an occasional clue, not a screening criterion.

A second misconception holds that constant itch means malignancy and intermittent itch means benignity. Biology does not respect that line: nerve sensitization can produce paroxysmal firing, and inflammation waxes and wanes. Conversely, a benign eczema patch can itch relentlessly for weeks.

A third is that itch localized to a mole implies the mole is transforming. Localized itch should prompt inspection, but the differential includes inflamed nevi, insect reactions, and dermatitis. The practical upshot is simple: judge the lesion, not just the sensation.

Practical Actions and Red Flags

Any lesion that is new, changing in size, shape, or color, or asymmetric warrants a professional skin examination regardless of itch. Itch confined to a single pigmented lesion, especially one that has recently changed, should be evaluated within weeks rather than months. A non-healing pink or flesh-colored nodule that itches belongs in the differential for amelanotic melanoma. New itch in a pre-existing mole, particularly with bleeding, crusting, or tenderness, is a red flag for prompt biopsy consideration. Widespread itch without a visible skin cause deserves a general medical workup, since systemic disease can produce pruritus independent of any mole. Do not treat lesion itch with repeated topical steroids without diagnosis; suppression can delay recognition of a growing tumor.

For clinicians, dermoscopy and, where indicated, excisional biopsy remain the decisive steps. No symptom pattern substitutes for histopathology. For patients, the actionable threshold is a lesion that is changing or stands out, not a lesion that itches a certain way.

Why Itch Timing and Behavior Matter Less Than You Think

The time course of melanoma itch is unpredictable, which is why "constant" is the wrong question. Itch may precede visible change, accompany it, or appear late. The table below summarizes how itch behaves across contexts, with the caveat that these are patterns rather than rules.

Context Typical itch pattern Diagnostic weight
Benign nevus Rare, mild, often from dryness or friction Low
Inflamed or irritated nevus Intermittent, improves with removal of irritant Low to moderate
Superficial spreading melanoma Occasional, focal, may precede other changes Moderate
Nodular melanoma Often absent; may be focal if present Low if absent
Amelanotic melanoma Variable, sometimes prominent Moderate, since itch prompts attention
Basal cell carcinoma Common, often intermittent Nonspecific
Eczema or psoriasis Frequent, chronic, diffuse or patchy Points away from melanoma

The table makes the reconciliation explicit: a single threshold cannot separate melanoma itch from benign itch. What separates them is the lesion's morphology and evolution, plus the presence of red flags such as bleeding or rapid growth. Itch is a prompt to look, not a verdict.

A timeline view helps patients and clinicians calibrate urgency. The intervals below reflect general dermatologic practice patterns rather than a single validated schedule.

Time point What to do Rationale
Day 0 Note the lesion's size, color, border, and itch pattern Creates a baseline for comparison
Days 1 to 7 Avoid scratching and irritants; photograph the lesion Reduces confounding inflammation
Week 1 to 2 If unchanged and low-risk, monitor; if changing, book a visit Captures evolution, the key signal
Week 2 to 4 Dermatologic examination with dermoscopy if any red flag Enables early biopsy decision
Week 4 to 6 Excisional biopsy if suspicion persists Histology is definitive
Beyond 6 weeks Do not let a suspicious lesion drift; re-evaluate Delay can affect stage at diagnosis

Limitations of What the Evidence Supports

The honest limit is this: itch prevalence figures come from heterogeneous case series with different definitions and ascertainment methods, and no validated tool scores melanoma-associated itch. Correlation between itch and tumor depth or stage is inconsistent across studies, so itch cannot be used prognostically. Antihistamine response data are largely anecdotal in this context.

Itch also interacts with anxiety and attention, which can amplify perception and complicate self-report. That does not make the symptom unreal; it makes it unreliable as a standalone signal. The defensible conclusion is narrow and useful: melanoma can itch, usually intermittently, sometimes prominently in amelanotic and acral variants, and the symptom should trigger lesion assessment rather than reassurance. Constant itch is not the rule, and its absence is not a clean bill of health.